The effect of colchicin on pain and function of patients with primary knee osteoarthritis

Subject Areas : علوم پزشکی

Mohammad  Mahdi Nejad Kashani ¹ (استادیار، دانشکده پزشکی، دانشگاه آزاد اسلامی مشهد، مشهد، ایران.)
Atefeh  Gilan Varnosfaderani ² (دانشجوی رشته پزشکی، دانشکده پزشکی، دانشگاه ازاد اسلامی مشهد، مشهد، ایران.)

Received: 2017-06-05 Accepted : 2017-06-05 Published : 2013-11-22

Keywords: Colchicine, pain, Osteoarthritis, Knee function,

Abstract :

Background and objective:As crystals may contribute to inflammation in osteoarthritis (OA), it is hypothesized that colchicines may affect on symptoms of patients with primary knee OA. Our objective was to evaluate the symptomatic benefits of colchicines on pain and function of patients with primary knee OA. Methods:  There were 180 patients in two groups (90 in colchicines and 90 in control group), enrolled in this study. Those patients with chronic hepatitis, gastrointestinal or hematologic diseases were excluded. At the first, age, sex, pain and knee function were registered. Using visual analogue scale (VAS) for pain and koos ps criteria for knee function. The Case group received 0.5mg colchicines twice a day and both groups received diclophenac in order to use if they had pain. Pain and knee function was measured again after 3 months. For analyzes SPSS v.20 and Statistica v.10 has been used. Results:  Mean age of patients was 60±5.4 years (50-70), and 53.9% were women. There was no significant difference between two groups considering percentage of pain relief (P>0.05). Also there was no significant correlation between pain relief percentage and age, sex, or affected side. But function of knee was significantly higher in case group after 3months (P=0.019).  The patients function recovery percentage was statically significant in case group (P=0.001). The relation of function with age (less than 60) P=0.001, sex (women) P=0.004 and affected side (Bilateral) P=0.003 was significant. Conclusion:More studies are needed in order to routine usage of colchicines in osteoarthritis.  

References:

 

1)    Felson DT. Osteoarthritis of the Knee. N Engl J Med. 2006; 354(6): 841-8.

 

2)    Felson DT, Brandt KD, Doherty M, Lohmander LS.  Epidemiology of osteoarthritis. J Osteoarthritis. 2003:9(2):225-229.

 

3)    Guccione AA¹, Felson DT, Anderson JJ, Anthony JM, Zhang Y, Wilson PW, Kelly-Hayes M, Wolf PA, Kreger BE, Kannel WB. The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. Am J Public Health. 1994 Mar;84(3):351-8.

 

4)    Fuerst M, Lammers L, Schäfer F, Niggemeyer O, Steinhagen J, Lohmann CH, Rüther W.  Investigation of calcium crystals in OA knees. Rheumatol Int. 2010 Mar;30(5):623-31. Epub 2009 Jul 29.

 

5)    Derfus BA, Kurian JB, Butler JJ, Daft LJ, Carrera GF, Ryan LM, Rosenthal AK. The high prevalence of pathologic calcium crystals in pre-operative knees. J Rheumatol. 2002 Mar;29(3):570-4.

 

6)    Viriyavejkul P, Wilairatana V, Tanavalee A, Jaovisidha K. Comparison of characteristics of patients with and without calcium pyrophosphate dihydrate crystal deposition disease who underwent total knee replacement surgery for osteoarthritis. Osteoarthritis Cartilage. 2007 Feb;15(2):232-5.

 

7)            Reuge L, Van Linthoudt D, Gerster JC. Local deposition of calcium pyrophosphate crystals in evolution of knee osteoarthritis. Clin Rheumatol. 2001;20(6):428-31.

8)    Halverson PB, McCarty DJ. Patterns of radiographic abnormalities associated with basic calcium phosphate and calcium pyrophosphate dihydrate crystal deposition in the knee. Ann Rheum Dis. 1986 Jul;45(7):603-5.

 

9)    Liu YZ, Jackson AP, Cosgrove SD. Contribution of calcium-containing crystals to cartilage degradation and synovial inflammation in osteoarthritis. Osteoarthritis Cartilage. 2009 Oct;17 (10):1333-40.

 

 

10)                Martínez Sanchis A, Pascual E. Intracellular and extracellular CPPD crystals are a regular feature in synovial fluid from uninflamed joints of patients with CPPD related arthropathy. Ann Rheum Dis. 2005 Dec;64(12):1769-72.

 

11)                TrevorA J , Katzung B G, Masters S B.Katzung & Trevor's Pharmacology Examination and Board Review.9^th ed. Philadelphia: McGraw-Hill; 2010.p.366-371.

 

12)                Das SK, Ramakrishnan S, Mishra K, Srivastava R, Agarwal GG, Singh R, Sircar AR. A randomized controlled trial to evaluate the slow-acting symptom-modifying effects of colchicine in osteoarthritis of the knee: a preliminary report. Arthritis Rheum. 2002 Jun 15;47(3):280-4.

 

13)                Nguyen C, Bazin D, Daudon M, Chatrolliet A, Hannouche D, Bianchi A, Come D, So A, Busso N, Lioté F, Ea HK. Revisiting spatial distribution and biochemical composition of calcium-containing crystals in human osteoarthritic articular cartilage. Arthritis Res Ther. 2013 Sep 3;15(5):R103.

 

14)                Viriyavejkul P, Wilairatana V, Tanavalee A, Jaovisidha K. Comparison of characteristics of patients with and without calcium pyrophosphate dihydrate crystal deposition disease who underwent total knee replacement surgery for osteoarthritis. Osteoarthritis Cartilage. 2007 Feb;15(2):232-5.

 

15)                Louthrenoo W, Sukitawut W. Calcium pyrophosphate dihydrate crystal deposition: a clinical and laboratory analysis of 91 Thai patients. J Med Assoc Thai. 1999 Jun;82(6):569-76.

 

16)                Reuge L, Van Linthoudt D, Gerster JC. Local deposition of calcium pyrophosphate crystals in evolution of knee osteoarthritis. Clin Rheumatol. 2001;20(6):428-31.

 

 Andres M, Sivera F, Pascual E. Methotrexate is an option for patients with refractory calcium pyrophosphate crystal arthritis. J Clin Rheumatol. 2012 Aug;18(5):234-6.